ArticlehLife2023
Structural basis of Semliki Forest virus entry using the very-low-density lipoprotein receptor.
Article in hLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alphaviruses are a group of important viruses that cause significant diseases in humans. Among them, Semliki Forest virus (SFV) not only causes symptoms such as joint pain but also infects neuron cells and induces encephalitis in rodents. Recently, the very-low-density lipoprotein receptor (VLDLR) was identified as the cellular receptor for SFV entry. In this study, we present the cryo-electron microscopy structure of SFV bound to human VLDLR. VLDLR targets E1-DIII region of SFV using its membrane-distal LDLR class A (LA) repeats. Structural and functional analyses emphasize the synergistic role of multiple VLDLR repeats in the SFV entry. Remarkably, VLDLR's binding mode to SFV closely mirrors that of minor group human rhinoviruses but differs significantly from other alphaviruses' interactions with receptors in the canyon region of the E protein. We also assessed SFV binding to VLDLR or apolipoprotein E receptor 2 (ApoER2) proteins in horses and mosquitoes and revealed their use of multiple but different LA repeats for binding. Our findings illuminate SFV's cross-species infectivity, offering insights into potential antiviral strategies against alphavirus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.